EU/3/19/2158

Table of contents

About

On 29 May 2019, orphan designation (EU/3/19/2158) was granted by the European Commission to MWB Consulting S.A.R.L., France, for (S)-3-((3-(1-((6-(3,4-dimethoxyphenyl)pryazin-2-yl)amino)ethyl)phenyl)carbamoyl)-5-methylpridin-1-ium (also known as GB002) for the treatment of pulmonary arterial hypertension.

Key facts

Active substance
(S)-3-((3-(1-((6-(3,4-dimethoxyphenyl)pryazin-2-yl)amino)ethyl)phenyl)carbamoyl)-5-methylpridin-1-ium
Disease / condition
Treatment of pulmonary arterial hypertension
Date of first decision
29/05/2019
Outcome
Positive
EU designation number
EU/3/19/2158

Sponsor's contact details

MWB Consulting S.A.R.L.
1 La Cour
50210 Belval
France
Tel. +33 2343 87120
E-mail: regaffairs@mwbconsulting.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating